VNS is an already-established treatment for conditions such as epilepsy, depression, and stroke rehabilitation. Image credit: Shutterstock/pixelparticle.

Tivic Health has completed enrolment in a study being conducted to finetune its non-invasive vagus nerve stimulation (VNS) device that the company hopes to deploy in clinical indications not properly addressed with currently available options.

The optimisation study, being conducted at Northwell Health’s research arm the Feinstein Institute of Bioelectronic Medicine, aims to identify device parameters that optimally influence autonomic nervous system (ANS) function.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The vagus nerve is a key part of the autonomic nervous system and is the longest nerve in the body. It contains both motor and sensory functions and is responsible for various processes such as heart rate, digestion, and mood, amongst others. VNS is an already-established treatment for conditions such as epilepsy, depression, and stroke rehabilitation. In the case of epilepsy, the neuromodulation treatment works by sending electrical pulses to the brain to stabilise irregular neural activity.

Tivic is looking to find out information relating to frequency and duration of potential treatments with its technology. Importantly, results from the study will help the company target and prioritise clinical indications that it “expects to carry forward into further testing and commercial development.” The Nasdaq-listed company said it expects the trial to be finished in early 2025.

Tivic Health’s chief scientific officer Blake Gurfein said: “This study is the next step in moving us closer to potential FDA approval of a non-invasive treatment for clinical indications that are inadequately addressed by the current treatment options.”

Tivic’s CEO Jennifer Ernst highlighted the limitations in implanted VNS technologies, which are “not always appropriate for certain clinical scenarios.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The global neuromodulation device market is forecast to grow to nearly $11bn by 2033, up from $5.7bn in 2023, as per analysis by GlobalData. Medtronic is currently the leader in terms of market share, with Boston Scientific and Abbott also key players. The vagus nerve stimulator segment is predicted to contribute $1bn to the market in 2033, as per GlobalData.

California-based Tivic already has a product on the market called ClearUp. The US Food and Drug Administration (FDA)-cleared transcutaneous electrical nerve stimulator is indicated to relieve congestion and sinus pain. In 2021, the FDA expanded clearance to include congestion from allergies, the flu, and the common cold, in addition to established clearance in treating allergy-related sinus pain caused by seasonal and year-round allergies.